Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.

National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group.

N Engl J Med. 1991 Jul 11;325(2):73-80.

2.
5.

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, et al.

N Engl J Med. 1993 Jul 29;329(5):297-303.

6.

Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection.

Mofenson LM, Moye J Jr.

Pediatr Res. 1993 Jan;33(1 Suppl):S80-7; discussion S87-9. Review.

PMID:
8433880
7.

Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients.

Crow ME.

Am J Health Syst Pharm. 1995 Apr 15;52(8):803-11. Review.

PMID:
7634115
8.
9.

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, et al.

N Engl J Med. 1992 Feb 13;326(7):437-43.

10.

A controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection.

Kiehl MG, Stoll R, Broder M, Mueller C, Foerster EC, Domschke W.

Arch Intern Med. 1996 Dec 9-23;156(22):2545-50.

PMID:
8951297
11.

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al.

Ann Intern Med. 1990 May 15;112(10):727-37.

PMID:
1970466
12.

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.

El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, Zeh D, Gallagher B, Mannheimer SB, Martinez A, Gordin F.

N Engl J Med. 2000 Apr 13;342(15):1085-92.

13.

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection.

Intravenous Immunoglobulin Collaborative Study Group, Cometta A, Baumgartner J-D, Lee ML, Hanique G, Glauser M-P.

N Engl J Med. 1992 Jul 23;327(4):234-40.

14.

A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.

Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, Philips JB 3rd, Edwards W, Lucey JF, et al.

N Engl J Med. 1994 Apr 21;330(16):1107-13.

15.
16.

A controlled trial of zidovudine in primary human immunodeficiency virus infection.

Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L, et al.

N Engl J Med. 1995 Aug 17;333(7):408-13. Erratum in: N Engl J Med 1995 Nov 16;333(20):1367.

17.

Spectrum of disease in persons with human immunodeficiency virus infection in the United States.

Farizo KM, Buehler JW, Chamberland ME, Whyte BM, Froelicher ES, Hopkins SG, Reed CM, Mokotoff ED, Cohn DL, Troxler S, et al.

JAMA. 1992 Apr 1;267(13):1798-805.

PMID:
1347573
18.

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators.

Lancet Respir Med. 2015 Mar;3(3):190-200. doi: 10.1016/S2213-2600(15)00037-5. Epub 2015 Feb 26.

19.

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.

Pediatrics. 1997 Mar;99(3):454-61.

PMID:
9041304
20.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.

N Engl J Med. 1994 Nov 3;331(18):1173-80.

Supplemental Content

Support Center